Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 13/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.52 |
| ▸ | KIT | P10721 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | FLT3 | P36888 | 2/20 | 0.52 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.52 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.39 |
| ▸ | USP2 | O75604 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12675283 | 0.89 | CYP3A4 (0.51) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL15266925 | 0.83 | L3MBTL1 (0.56) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL2599968 | 0.82 | CYP3A4 (0.55) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL2599952 | 0.81 | CYP3A4 (0.58) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL2599950 | 0.80 | CYP3A4 (0.44) | CYP3A4CYP2C19KITKDRFLT3 | |
| SCHEMBL12675776 | 0.79 | CYP3A4 (0.54) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL12675284 | 0.78 | CYP3A4 (0.51) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL2599962 | 0.77 | CYP3A4 (0.53) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL12675288 | 0.76 | CYP3A4 (0.48) | CYP3A4CYP2C19CYP2C9KITKDR | |
| SCHEMBL15660562 | 0.75 | CYP1A2 (0.61) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2496086-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-9260437-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260437-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150166547-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150166547-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-8912204-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912204-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20120165329-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2012-06-28 | — | — | US | disclosed |
| US-20120165329-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2012-06-28 | — | — | US | disclosed |
| US-8158636-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158636-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166547-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | CYP3A4 3734/4885CYP2C19 3085/4885CYP2C9 2880/4885 |
| US-20090286782-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | CYP3A4 3734/4885CYP2C19 3085/4885CYP2C9 2880/4885 |
| US-20120165329-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKDC, PRKACA, PRKACG | CYP3A4 3734/4885CYP2C19 3085/4885CYP2C9 2880/4885 |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, FLT3, BRAF | CYP3A4 3717/4885CYP2C19 4018/4885CYP2C9 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.